###begin article-title 0
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TGF-beta and IL-10 Production by HIV-Specific CD8+ T Cells Is Regulated by CTLA-4 Signaling on CD4+ T Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: ME HC. Performed the experiments: ME CMB. Analyzed the data: ME. Contributed reagents/materials/analysis tools: CMB CAB NGJ SB DRB HC. Wrote the paper: ME HC.
###end p 1
###begin p 2
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 239 242 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 350 353 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 661 664 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 764 767 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 879 882 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1042 1045 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Immune dysregulation in HIV-1 infection is associated with increased expression of inhibitory molecules such as CTLA-4, TGF-beta, and IL-10. In this study we examined one potential mechanism for regulating TGF-beta and IL-10 expression by HIV-specific suppressor CD8+ T cells. No overlap between TGF-beta, IL-10, and IFN-gamma cytokine production by HIV-specific CD8+ T cells was observed. TGF-beta positive and IL-10 positive cells were FOXP3 negative, CD25 negative, and displayed a heterogeneous surface expression of CD127. TGF-beta and IL-10 positive CD8+ T cells did not express CTLA-4. Nevertheless, CTLA-4 blockade resulted in a significant decrease in HIV-specific TGF-beta positive and IL-10 positive CD8+ T cell responses, and a concomitant increase in HIV-specific IFN-gamma positive CD8+ T cell responses. Depletion of CD4+ T cells abrogated the impact of CTLA-4 on HIV-specific TGF-beta positive and IL-10 positive CD8+ T cells. Our study suggests that CTLA-4 Signaling on CD4+ T cells regulates the inhibitory functions of the HIV-specific suppressor CD8+ T cells.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 161 164 161 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Scotto1">[1]</xref>
###xml 165 168 165 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Cosmi1">[4]</xref>
###xml 247 250 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Levings1">[5]</xref>
###xml 252 255 249 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Weiner1">[6]</xref>
###xml 336 339 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Balashov1">[7]</xref>
###xml 340 344 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Filaci3">[10]</xref>
###xml 404 408 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kumar1">[11]</xref>
###xml 410 414 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Jiang1">[12]</xref>
###xml 451 454 448 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Scotto1">[1]</xref>
###xml 456 459 453 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Cosmi1">[4]</xref>
###xml 461 465 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Manavalan1">[13]</xref>
###xml 467 471 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Bisikirska1">[14]</xref>
###xml 585 589 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Letterio1">[15]</xref>
###xml 590 594 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Garba1">[18]</xref>
###xml 636 640 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Chen1">[19]</xref>
###xml 641 645 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Zheng1">[21]</xref>
###xml 702 706 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Sung1">[22]</xref>
###xml 803 807 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Sharma1">[23]</xref>
###xml 809 813 794 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Reinhold1">[24]</xref>
###xml 868 872 853 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Sharma1">[23]</xref>
###xml 873 877 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Zanussi1">[25]</xref>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
Suppressor CD8+ T cells (CD8+ Ts) exert their inhibitory effects on T cell proliferation and cytokine production through a cell-cell contact-dependent mechanism [1]-[4], and by secreting the immunosuppressive cytokines interleukin-10 and TGF-beta [5], [6]. CD8+ Ts mediate non-antigen specific suppression of T cell responses via IL-10 [7]-[10]. These suppressor CD8+ T cells are typically CD28 negative [11], [12] and express CD25, FOXP3, and CTLA-4 [1], [4], [13], [14]. Transforming growth factor beta (TGF-beta) is another immunosuppressive cytokine that inhibits T cell functions [15]-[18]. TGF-beta up-regulates CTLA-4 expression [19]-[21] and suppresses T cell proliferation and IL-2 production [22]. Increased TGF-beta and IL-10 is associated with disease progression in HIV-1-infected patients [23], [24], and likely influences the antiviral immune responses [23]-[25].
###end p 4
###begin p 5
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Chen2">[26]</xref>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Greenwald1">[27]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Greenwald1">[27]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-vonBoehmer1">[28]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kaufmann1">[29]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Steiner1">[31]</xref>
###xml 665 669 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kaufmann1">[29]</xref>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Riley1">[32]</xref>
###xml 984 988 984 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Andersson1">[33]</xref>
###xml 488 491 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 548 551 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 630 633 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 772 775 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
###xml 868 873 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 950 953 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1114 1117 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is overexpressed on activated T cells and inhibits IL-2 production and cell cycle progression by binding to its ligands B7-1 (CD80) and B7-2 (CD86) [26], [27]. CTLA-4 is also constitutively expressed on regulatory CD4+ T cells (Treg) and mediates T cell suppression [27]. Treg inhibits T cells via direct cell-cell interaction or indirectly by an antigen-presenting cell-mediated mechanism [28]. High CTLA-4 expression correlates with markers of HIV disease progression [29]-[31]. CTLA-4 is upregulated on HIV-specific CD4+, but not CD8+, T cells and in vitro blockade of CTLA-4 augments HIV-specific CD4+ T cell functions [29]. Upregulation of CTLA-4 also increases CCR5 expression and enhances susceptibility of CD4+ T cells to HIV infection [32]. The frequency of CTLA-4 positive Treg is increased in patients with chronic HIV-1 infection and is suspected to play a critical immunomodulatory role leading HIV-associated immune dysfunction [33]. In this study, we explore the relationship between CTLA-4 positive CD4+ T cells and the production of TGF-beta and IL-10 by HIV-specific CD8+ T cells.
###end p 5
###begin title 6
Materials and Methods
###end title 6
###begin title 7
Study Subjects and Samples
###end title 7
###begin p 8
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Moss1">[34]</xref>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 395 400 <span type="species:ncbi:9606">Human</span>
###xml 425 437 <span type="species:ncbi:9606">participants</span>
###xml 487 499 <span type="species:ncbi:9606">participants</span>
###xml 566 569 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV positive volunteers (n = 37) were recruited from the "The Research in Access to Care in the Homeless (REACH)" cohort in San Francisco as previously described [2], [34]. Demographic information and CD4+ T cell count was obtained at the time of enrollment and blood draw. Institutional Review Board approvals were obtained from the California Department of Public Health and UCSF Committee on Human Research, and all study participants gave written informed consent. None of the study participants have received antiretroviral therapy (ART) for at least 6 months. HIV RNA level was determined from plasma using the Roche Amplicor 1.5 (Roche, Branchburg, New Jersey), as per manufacturer's recommendations. Peripheral blood mononuclear cells (PBMC) were separated and cryopreserved in liquid nitrogen until assay time.
###end p 8
###begin title 9
Antigens
###end title 9
###begin p 10
###xml 380 384 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-McEvers1">[35]</xref>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Peptides corresponding to the clade B consensus sequences of HIV-1 for Gag and Nef were synthesized as 15 amino acids (a.a.) overlapping by 11 a.a. (Mitochor Mimotopes,Victoria, Australia). Synthetic peptides for Gag (total  = 123), and Nef (total  = 49), used for all T cell assays were pooled into one single pool of peptides with final concentration of 1 microg/ml per peptide [35].
###end p 10
###begin title 11
Flow-Based Intracellular Cytokine Staining
###end title 11
###begin p 12
###xml 106 110 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei2">[36]</xref>
###xml 122 123 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 204 205 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 436 437 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1042 1046 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Perfetto1">[37]</xref>
###xml 13 16 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Detection of HIV-specific TGF-beta, IL-10, and IFN-gamma production was performed as previously described [36]. PBMC (1x106) were incubated with Gag or Nef peptide pools for 2 hours at 37degreesC in 5% CO2 in the presence of one of these following antibodies: anti-TGF-beta R II (2 microg/ml, R&D systems, Minneapolis MN), anti-CTLA-4 (5 microg/ml, BD Phamingen), or the respective isotype control for 12-14 hours at 37degreesC in 5% CO2 in the presence of co-stimulatory anti-CD49d (1 microg/ml, Becton-Dickinson) and Golgi stop (BD Pharmigen). Phorbol myristate acetate (PMA, 50 ng/ml) and ionomycin (1 microg/ml; Sigma-Aldrich, St. Louis, MO), Lypopolysacccharide (LPS, 1 ng/ml; Sigma-Aldrich), and phytohaemagglutinin (PHA, 10 microg/ml; Sigma-Aldrich) were used as positive controls for TGF-beta, IL-10 and IFN-gamma production respectively. Media alone without antigen stimulation was used as negative control. All samples were stained with an amine reactive viability dye as a dead cell exclusion marker (Molecular probes, Eugene, OR) [37]. In some experiments depletion of CD4+ T cells was performed using the MACS CD4 depletion kit following the manufacturer's protocol (Miltenyi Biotec, Germany). Cells were then stained with specific combinations of the following antibodies: CD27 FITC, CD4 PerCP CY5.5, CD127 Alexa Fluor 647, CD8 PE CY7, CD3 AmCyan (BD Pharmigen). PBMC were permeabilized and stained with different combinations of the following antibodies: CTLA-4 APC, IL-10 PE, IL-10 APC, IFN-gamma FITC (BD Pharmigen), TGFbeta PE (Biotest Diagnostics, Denville, NJ), and analyzed by flow cytometry. A minimum of 30,000 CD3+ T cells per sample were acquired using a 6-color flow cytometer (LSRII, BD Biosciences) and analysis was performed by FLOWJO software (TreeStar, San Carlos, CA). Results were expressed as: Percent TGF-beta, IL-10, or IFN-gamma positive CD8+, T cells (Percent positive  =  % antigen-specific - % negative control). Responses greater than or equal to 0.1% and 2 times the background were considered positive. The extent of CTLA-4, CD27, and CD127 expression was also assessed. All volunteers demonstrated significant TGF-beta, IL-10, and IFN-gamma production following PMA/Ionomycin, LPS, and PHA stimulation respectively. Background expression was <0.1 percent.
###end p 12
###begin title 13
Flow-Based FOXP3 Staining Assay
###end title 13
###begin p 14
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Perfetto1">[37]</xref>
###xml 177 180 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC were stained for FOXP3 expression following the manufacturer's protocol (eBioscience, San Diego, CA) with some modifications [2]. Briefly, PBMC (1x106) were incubated with HIV peptide pools for 12-14 hrs as described above for intracellular cytokine staining. Cells were then stained with an amine reactive viability dye as a dead cell exclusion marker (Molecular probes) [37], and the following antibodies: FOXP3 FITC (eBioscience), TGF-beta PE, CD4 PerCP Cy5.5, CD8 PE CY7, CD25 allophycocyanin, and CD3 AmCyan (BD Pharmigen). Analysis was performed by flow cytometry as described above. The percentage of TGF-beta positive CD8+ T cells was determined and the extent of FOXP3 and CD25 expression was also assessed. Results were expressed as the fraction of TGF-beta positive cells that expressed FOXP3 or CD25 over the total number of TGF-beta positive cells (equivalent to 100%).
###end p 14
###begin title 15
Statistical Analysis
###end title 15
###begin p 16
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Groups were compared using the Mann-Whitney U test or the paired t test. Analysis was performed with PRISM software version 4.02 (Graph-Pad). Statistical significance was defined as p<0.05.
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TGF-beta, IL-10, and IFN-gamma Producing HIV-Specific CD8+ T Cells Are Distinct Populations
###end title 18
###begin p 19
###xml 108 112 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Garba1">[18]</xref>
###xml 114 118 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Zanussi1">[25]</xref>
###xml 120 124 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 265 272 259 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g001">Fig. 1A</xref>
###xml 452 453 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 682 689 665 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g001">Fig. 1B</xref>
###xml 1749 1753 1712 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 238 243 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 482 485 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 585 588 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 710 713 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1620 1623 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1687 1690 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1741 1744 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1809 1812 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1881 1884 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1977 1980 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Specific populations of HIV-specific CD8+ T cells have been shown to express high TGF-beta and IL-10 levels [18], [25], [38]. We first measured the frequency of Gag and Nef-specific TGF-beta positive and IL-10 positive CD8+ T cells in 37 HIV-1 infected volunteers (Fig. 1A). IFN-gamma production by Gag- and Nef-specific CD8+ T cells was determined concurrently. Volunteers had a median age of 45 years (range, 31-61), CD4+ T cell count of 168 cells/mm3 (range, 19-233), and median HIV plasma RNA of 132200 copies/ml (range, 19000-780000). Representative plots of the frequency of the HIV-specific TGF-beta positive, IL-10 positive, and IFN-gamma positive CD8+ T cells are shown in Fig. 1B. No overlap between HIV-specific CD8+ T cells producing TGF-beta, IL-10 or IFN-gamma was observed. All volunteers demonstrated significant Gag- (median  = 0.48%; range  = 0.1%-3.5%) and Nef- (median  = 0.4%; range  = 0.1%-2.2%) specific IFN-gamma positive CD8+ T cell responses. Fourteen and fifteen volunteers demonstrated significant Gag-, and Nef-, specific TGF-beta positive CD8+ T cell responses respectively (median  = 0.6%; range  = 0.15%-2.0%, and median  = 0.4%; range  = 0.1%-2.0% for Gag and Nef, respectively). Sixteen volunteers demonstrated significant Gag- (median  = 0.13%; range  = 0.1%-0.45%) and Nef- (median  = 0.19%; range  = 0.1%-0.6%) specific IL-10 positive CD8+ T cell responses. Differences in the frequencies of Gag- and Nef-specific TGF-beta (or IL-10) positive CD8+ T cell responses was not significant (p = 0.22 and p = 0.45 for TGF-beta and IL-10 respectively). We have previously demonstrated that HIV-specific IL-10 positive CD8+ T cells are increased in advanced HIV disease and are positively correlated with plasma HIV RNA [38]. No correlation was found between the frequency of the HIV-specific TGF-beta positive CD8+ T cells and the CD4 count or plasma HIV RNA (for Gag: p = 0.07 and p = 0.1, for Nef: p = 0.68 and p = 0.13, for CD4 count or plasma HIV RNA respectively; data not shown). However, the relatively small number of volunteers in the study limited the full examination of this relationship.
###end p 19
###begin title 20
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TGF-beta positive, IL-10 positive, and IFN-gamma positive HIV-specific CD8+ T cell populations are distinct.
###end title 20
###begin p 21
###xml 465 466 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 515 518 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC were stimulated with HIV peptides then stained with anti-IFN-gamma FITC, anti-TGF-beta PE, anti-CD3 AmCyan, anti-CD4 PerCP Cy5.5, and anti-CD8 PE Cy7, anti-IL-10 APC, and analyzed by flow cytometry. Samples were first gated on the CD3+/CD8+ lymphocyte population then the percent of TGF-beta, IFN-gamma, and IL-10 positive CD8+ T cells were determined. (A) Data from individuals with significant cytokine expression and analysis were performed by Mann-Whitney U test. (B) Representative plots of the number of HIV-specific CD8+ T cells expressing TGF-beta, IFN-gamma, and IL-10 after subtraction of the back ground values.
###end p 21
###begin title 22
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TGF-beta Receptor II Blockade Increases IFN-gamma Expression by HIV-Specific CD8+ T Cells
###end title 22
###begin p 23
###xml 97 100 97 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 212 216 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Letterio1">[15]</xref>
###xml 217 221 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Garba1">[18]</xref>
###xml 223 227 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Sharma1">[23]</xref>
###xml 229 233 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Reinhold1">[24]</xref>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 129 132 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 278 281 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 365 368 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 753 756 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have previously described the presence of suppressor HIV-specific IL-10 positive CD8+ T cells [2], [38]. We hypothesized that HIV-specific TGF-beta positive CD8+ T cells also exert immunosuppressive functions [15]-[18], [23], [24]. To determine the effect of TGF-beta on the HIV-specific effector functions (as measured by IFN-gamma production), PBMC from three HIV-positive volunteers with evidence of Gag- and Nef-specific TGF-beta positive CD8+ T cells were co-cultured in the presence of anti-TGF-beta receptor II Ab (or isotype control). Blocking of the TGF-beta receptor II led to increased Gag- and Nef-specific IFN-gamma positive CD8+ T cell responses (data not shown). These results suggest that TGF-beta production by CD8+ T cells inhibits HIV-specific effector functions.
###end p 23
###begin title 24
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analysis of the Immunophenotypic Profile of HIV-Specific TGF-beta Positive CD8+ T Cells
###end title 24
###begin p 25
###xml 115 118 115 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 548 554 542 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g002">Fig. 2</xref>
###xml 1046 1049 1027 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Scotto1">[1]</xref>
###xml 1051 1054 1032 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Cosmi1">[4]</xref>
###xml 1056 1060 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kumar1">[11]</xref>
###xml 1062 1066 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Jiang1">[12]</xref>
###xml 1068 1072 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Bisikirska2">[39]</xref>
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 193 196 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 307 310 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 456 459 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 556 559 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 789 792 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 913 916 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1021 1024 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have previously shown that the suppressor HIV-specific IL-10 positive CD8+ T cells were FOXP3 and CD25 negative [2], and displayed a heterogenous memory phenotype that was distinct from the HIV-specific effector CD8+ T cell population [38]. In this study, we examined the immunophenotypic profile of the HIV-specific TGF-beta positive CD8+ T cells. PBMC were stimulated with HIV peptides and the extent of FOXP3, CD25, CD127, and CD27 expression by the HIV-specific TGF-beta positive CD8+ T cells was assessed. Representative plots are shown in Fig. 2. HIV-specific TGF-beta positive CD8+ T cells were FOXP3 negative and CD25 negative. Similar to the IL-10 positive CD8+ Ts, Gag-specific TGF-beta positive CD8+ T cells displayed heterogeneous expression of CD27 and CD127. In contrast, HIV-specific IFN-gamma positive CD8+ T cells were CD27 and CD127 negative (data not shown). These results indicate that the HIV-specific TGF-beta positive CD8+ T cells are different from the population of suppressor CD8+ T cells in HIV negative individuals [1], [4], [11], [12], [39].
###end p 25
###begin title 26
###xml 53 56 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analysis of regulatory surface markers expression by HIV-specific TGF-beta positive CD8+ T cells.
###end title 26
###begin p 27
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 521 524 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC were stimulated with HIV peptides, then stained for various memory and regulatory markers and the percentage of TGF-beta positive CD8+ T cells was determined by flow cytometry. Samples were first gated on the CD3+/CD8+ lymphocyte population and then the percentages of TGF-beta positive cells were determined and the extent of FOXP3, CD127, CD25, and CD27 expression was also examined. Gating was performed using the fluorescence-minus-one (FMO) control for each marker. Representative plots of the phenotype of the HIV-specific CD8+ T cells expressing TGF-beta. The values marked with an asterisk represent the fraction of TGF-beta positive cells that express FOXP3, CD127, CD25, or CD27 over the total number of TGF-beta positive cells (equivalent to 100%).
###end p 27
###begin title 28
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CTLA-4 Blockade Decreases TGF-beta and IL-10 Expression by HIV-Specific CD8+ T Cells
###end title 28
###begin p 29
###xml 119 123 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kaufmann1">[29]</xref>
###xml 449 456 439 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g003">Fig. 3A</xref>
###xml 552 559 539 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g003">Fig. 3C</xref>
###xml 572 579 559 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g003">Fig. 3D</xref>
###xml 750 757 733 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g003">Fig. 3B</xref>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 186 189 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 244 247 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 529 532 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 695 698 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 851 854 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In vitro blockade of CTLA-4 engagement augments HIV-specific CD4+ T cell proliferation, IL-2, and IFN-gamma production [29]. We explored whether this inhibitory mechanism is involved in HIV-specific TGF-beta and IL-10 CD8+ T cells. PBMC from 6 HIV-positive volunteers with demonstrated Gag- and Nef-specific TGF-beta and IL-10 positive CD8+ T cell responses were incubated with anti-CTLA-4 Ab (or isotype control). Representative plots are shown in Fig. 3A. CTLA-4 blockade resulted in a significant decrease in the frequency of HIV-specific TGF-beta (Fig. 3C) and IL-10 (Fig. 3D) positive CD8+ T cell responses. In contrast, blockade of CTLA-4 led to a significant increase in the frequency of HIV-specific IFN-gamma positive CD8+ T cell responses (Fig. 3B). These results suggest that engagement of CTLA-4 regulates TGF-beta and IL-10 production by HIV-specific CD8+ T cells.
###end p 29
###begin title 30
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CTLA-4 blockade decreases TGF-beta and IL-10 expression by HIV-specific CD8+ T Cells.
###end title 30
###begin p 31
###xml 971 973 936 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t-</italic>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 444 447 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 577 580 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC (n = 6) were stimulated with HIV peptides in the presence of anti-CTLA4 (or isotype control), then stained with anti-IFN-gamma FITC, anti-TGF-beta PE, anti-IL-10 APC, anti-CD3 AmCyan, anti-CD4 PerCP CY5.5, anti-CD8 PE CY7, and analyzed by flow cytomerty. Samples were first gated on the CD3+/CD8+ lymphocyte population then the percent of TGF-beta, IL-10, and IFN-gamma positive cells were determined. Results were expressed as percent of HIV-specific CD8+ T cells expressing TGF-beta, IL-10, or IFN-gamma after subtraction of the back ground. (A) Representative plots of HIV-specific CD8+ T cells expressing TGF-beta, IL-10, or IFN-gamma in the presence or absence of anti-CTLA-4. (B-D) Dashed line represents the cutoff for significant TGF-beta (B), IL-10 (C), and IFN-gamma (D) expression. Percentages in between brackets are median values. The two dots joined by a line represent the values obtained from the same individual and analysis was performed by paired t-test.
###end p 31
###begin title 32
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-Specific TGF-beta and IL-10 Positive CD8+ T Cells Are CTLA-4 Negative
###end title 32
###begin p 33
###xml 51 55 51 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kaufmann1">[29]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Andersson1">[33]</xref>
###xml 248 254 245 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g004">Fig. 4</xref>
###xml 367 374 361 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g004">Fig. 4B</xref>
###xml 538 545 532 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g004">Fig. 4A</xref>
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CTLA-4 is upregulated in HIV-specific CD4+ T cells [29], particularly in patients with chronic HIV-1 infection [33]. We next determined whether CTLA-4 is also expressed on TGF-beta and IL-10 positive CD8+ T cells. Representative plots are shown in Fig. 4. We found no evidence of CTLA-4 expression on CD8+ T cells, including TGF-beta and IL-10 positive CD8+ T cells (Fig. 4B) as well as on CD8+ IFN+ T cells (data not shown). This is in contrast to the high CTLA-4 expression detected on CD4+ T cells (median  = 2.8%; range  = 1.3%-7.0%; Fig. 4A). The lack of CTLA-4 expression on the CD8+ T cells suggests that the effect of CTLA-4 blockade on the TGF-beta and IL-10 positive CD8+ T cells is mediated by an indirect mechanism.
###end p 33
###begin title 34
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-specific TGF-beta and IL-10 positive CD8+ T cells are CTLA-4 negative.
###end title 34
###begin p 35
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC were stimulated with HIV peptides then stained with anti-TGF-beta PE (or IL-10 PE), anti-CD3 AmCyan, anti-CD4 PerCP Cy5.5, anti-CD8 PE Cy7, anti-CTLA-4 APC, and analyzed by flow cytometry. Gating on the CTLA-4 positive cells was performed using the fluorescence-minus-one (FMO) control for CTLA-4. (A) Representative plots of samples that were first gated on the CD3+/CD4+ and CD3+/CD8+ lymphocyte population and then the percentages of CTLA-4 positive cells were determined. (B) Representative plots of samples that were first gated on the CD3+/CD8+ lymphocyte population and then the percent of TGF-beta and IL-10 positive cells that express CTLA-4 was determined after subtraction of the back ground values. The values marked with an asterisk represent the fraction of TGF-beta (or IL-10) positive cells that express CTLA-4 over the total number of TGF-beta (or IL-10) positive cells (equivalent to 100%). Plots are from three independent experiments yielding similar results.
###end p 35
###begin p 36
###xml 423 429 410 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008194-g005">Fig. 5</xref>
###xml 94 97 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 372 375 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 562 565 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 801 804 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We next attempted to further elucidate the role of CTLA-4 on TGF-beta and IL-10 production by HIV-specific CD8+ T cells. We depleted CD4+ T cells in order to examine the effect of CTLA-4 expression by these CD4+ T cells on TGF-beta and IL-10 production. Removal of CD4+ T cells fully abrogated the effect of CTLA-4 blockade on TGF-beta, IL-10, and IFN-gamma production by HIV-specific CD8+ T cells that we described above (Fig. 5). Adding back the autologous CD4+ T cells fully restored the effect of CTLA-4 blockade on TGF-beta-, IL-10-, and IFN-gamma-positive HIV-specific CD8+ T cells. While a relatively small number of volunteers were examined in the study, these results strongly support the role of CTLA-4 positive CD4+ T cells in the regulation of TGF-beta, IL-10, and IFN-gamma production by HIV-specific CD8+ T cells.
###end p 36
###begin title 37
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Removal of CD4+ T cells abrogates the effects of CTLA-4 blockade on HIV-specific CD8+ T Cells.
###end title 37
###begin p 38
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 455 458 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PBMC (or CD4 negative PBMC) were stimulated with HIV peptides in the presence of anti-CTLA4 (or isotype control), then stained with anti-IFN-gamma FITC, anti-TGF-beta PE, IL-10 APC, anti-CD3 Am Cyan, anti-CD4 PerCP CY5.5, anti-CD8 PE CY7, and analyzed by flow cytomerty. Samples were first gated on the CD3+/CD8+ lymphocyte population then the percent of TGF-beta, IL-10, and IFN-gamma positive cells were determined. Results were expressed as percent of HIV-specific CD8+ T cells expressing TGF-beta, IL-10, or IFN-gamma after subtraction of the back ground. Representative plots of (A) Gag and (B) Nef-specific CD8+ T cells expressing TGF-beta, IL-10, or IFN-gamma in the presence or absence of anti-CTLA-4. Data plots shown are representative of three volunteers examined in three independent experiments yielding similar results.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-deStGroth1">[40]</xref>
###xml 520 523 520 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Scotto1">[1]</xref>
###xml 525 528 525 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 530 533 530 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Cosmi1">[4]</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 658 662 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Rouse1">[41]</xref>
###xml 663 667 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Endharti1">[43]</xref>
###xml 118 123 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 366 369 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 506 509 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The mechanisms leading to the progressive loss of immune function and eventual failure of T cell responses in chronic HIV-1 infection remain unresolved. One hypothesis is that effector T cells succumb to an immunosuppressive environment. Multiple regulatory pathways are functionally altered and different CD4+ Treg subpopulations are induced in different stages of HIV infection [reviewed in [40]]. Similarly, distinct subpopulations of CD8+ Ts may also contribute to the immune dysregulation observed in HIV infection [1], [2], [4], [38]. Suppressor CD8+ T cells produce IL-10 and TGF-beta, and mediate non-antigen specific suppression of T cell responses [41]-[43].
###end p 40
###begin p 41
###xml 241 245 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Garba1">[18]</xref>
###xml 247 251 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 411 414 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 450 454 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 663 667 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei2">[36]</xref>
###xml 1594 1598 1569 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Garba1">[18]</xref>
###xml 93 96 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 147 150 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 336 339 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 628 631 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 857 860 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1052 1055 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1164 1167 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our current study focuses on the mechanisms of suppression utilized by CD8+ Ts in inhibiting HIV-specific CD8+ T cell responses. The inhibition of HIV-specific T-cell responses by CD8+ Ts has been attributed to TGF-beta and IL-10 production [18], [38]. We have previously described the presence of IL-10 positive CD8+ Ts that inhibited HIV-specific cytolysis and IL-2 production by direct cell-cell interaction [2], and indirectly by releasing IL-10 [38]. The presence of these suppressor IL-10 positive CD8+ T cells was associated with increased expression of the inhibitory receptor programmed cell death-1(PD-1) on exhausted HIV-specific effector CD8+ T cells [36]. However, blockade of the PD-1/PDL-1 pathway did not prevent suppression, suggesting that PD-1 engagement is not a mechanism utilized by the IL-10 positive CD8+ T cells. We now describe an HIV-specific TGF-beta positive CD8+ T cell population that is distinct from IL-10 positive CD8+ Ts. Blocking the binding of TGF-beta to its receptor resulted in increased IFN-gamma expression by HIV-specific CD8+ T cells. We postulate that these TGF-beta positive CD8+ T cells exert an inhibitory effect on HIV-specific effector function in vitro. Nevertheless, the suppressive impact of these TGF-beta CD8+ T cells in vivo remains unknown, and direct cell-cell contact may be required for the these TGF-beta positive CD8+ T cells to exert their maximum inhibitory effect. The intriguing role by which distinct antigen-specificity of these TGF-beta positive CD8+ T cells contributes to the level of suppression is remains to be explored [18].
###end p 41
###begin p 42
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 239 243 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kornfeld1">[44]</xref>
###xml 650 654 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei3">[38]</xref>
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 171 174 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 467 470 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 702 705 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have previously shown that IL-10 positive CD8+ Ts are observed in late HIV disease [38]. The induction and detection of TGF-beta positive CD8+ T cells in the course of HIV disease is still unknown but may develop earlier in HIV disease [44]. Because TGF-beta is a key regulator in the suppressive signaling pathways implicated in immune regulation, signaling through TGF-beta receptor may promote differential and temporal effect on T cells in different stages of HIV disease. We have shown previously that the concomitant presence of Gag- and Nef-specific IL-10 positive CD8+ Ts augmented the in vitro suppressive effect on effector CD8+ T cells [38]. We postulate that the concomitant presence of HIV-specific IL-10 positive and TGF-beta positive CD8+ T cells will promote additive suppression of effector CD8+ T cell responses.
###end p 42
###begin p 43
###xml 218 221 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 466 469 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Scotto1">[1]</xref>
###xml 471 474 465 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-BaecherAllan1">[3]</xref>
###xml 476 479 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Cosmi1">[4]</xref>
###xml 481 485 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Manavalan1">[13]</xref>
###xml 487 491 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Bisikirska1">[14]</xref>
###xml 493 497 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Asseman1">[45]</xref>
###xml 498 502 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Khattri1">[47]</xref>
###xml 627 631 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Liu1">[48]</xref>
###xml 633 637 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Seddiki1">[49]</xref>
###xml 714 717 708 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Elrefaei1">[2]</xref>
###xml 452 455 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this study we describe the presence of TGF-beta positive CD8+ T cells with multiple antigen specificities that displayed an immunophenotype profile that is similar to our previously described IL-10 positive CD8+ Ts [2]. These TGF-beta positive CD8+ T cells do not display the immunophenotypic patterns traditionally attributed to regulatory T cells. FOXP3 and CD25 surface expressions are the hallmark for identifying CD8+ Ts in diseases other than HIV infection [1], [3], [4], [13], [14], [45]-[47]. The lack of CD127 expression on FOXP3 positive CD4+ T cells is used to distinguish between regulatory and effector T cells [48], [49]. However, FOXP3 negative and CD25 negative CD8+ Ts have also been described [2]. The mechanisms leading to the induction of these TGF-beta positive CD8+ T cells likely share similar pathways with other regulatory T cells. One key question is whether CD4+Treg are required for the generation and suppressive function of CD8+Ts.
###end p 43
###begin p 44
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-vonBoehmer1">[28]</xref>
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Sansom1">[50]</xref>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Taylor1">[51]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Kaufmann1">[29]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Steiner1">[31]</xref>
###xml 657 661 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008194-Greenwald1">[27]</xref>
###xml 237 240 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 369 372 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 532 535 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 701 704 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Inhibitory functions of regulatory T cells are mediated by direct binding of CTLA-4 and by cytokine production [28], [50], [51]. Surprisingly, engagement of CTLA-4 prevented the production of suppressive cytokines by the CTLA-4 negative HIV-specific CD8+ T cells. We propose a model by which CTLA-4 positive CD4+ T cells indirectly influence the inhibitory function of HIV-specific CD8+ Ts by CTLA-4 engagement. The abrogation of anti-CTLA-4 blockade in the absence of CD4+ T cells supports our hypothesis. CTLA-4 is upregulated on HIV-specific CD4+ T cells in advanced disease [29]-[31], and CTLA-4 is also constitutively expressed on regulatory CD4+ Treg [27]. Clearly, the presence of CD4+ Treg in HIV infection adds to the complexity of immune regulation and suppression. The influence of CTLA-4 expression by populations other than CD4+ T cells on the effectiveness of CD8+ suppressor T cells remains to be determined.
###end p 44
###begin p 45
###xml 35 38 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 109 112 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 381 384 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 431 434 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 542 545 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In summary, our study described an HIV-specific CD8+ T cell population that mediated in vitro suppression of HIV-specific effector function through the production of TGF-beta. These TGF-beta positive CD8+ T cells most likely confer regulatory properties. Nevertheless, the relative contribution of these TGF-beta positive CD8+ T cells to the general immune dysfunction observed in HIV infection is currently unknown. The impact of HIV-specific CD8+ Ts remains an intriguing new research area that offers new direction into the consequence of HIV immunopathogenesis. Further studies should focus on the pathways by which complex immune regulatory mechanisms modulate the adaptive, antiviral immune response. The ability to manipulate and regulate effective antiviral immunity provides an approach toward decreasing the number of infected cells and improving disease outcome.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells.
###end article-title 47
###begin article-title 48
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-specific IL-10-positive CD8+ T cells suppress cytolysis and IL-2 production by CD8+ T cells.
###end article-title 48
###begin article-title 49
###xml 33 38 <span type="species:ncbi:9606">human</span>
CD4+CD25high regulatory cells in human peripheral blood.
###end article-title 49
###begin article-title 50
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes.
###end article-title 50
###begin article-title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells.
###end article-title 51
###begin article-title 52
Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells.
###end article-title 52
###begin article-title 53
###xml 44 49 <span type="species:ncbi:9606">human</span>
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.
###end article-title 53
###begin article-title 54
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus.
###end article-title 54
###begin article-title 55
Non-antigen specific CD8+ T suppressor lymphocytes.
###end article-title 55
###begin article-title 56
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
###end article-title 56
###begin article-title 57
Homeostatic control of immunity by TCR peptide-specific Tregs.
###end article-title 57
###begin article-title 58
An integrated view of suppressor T cell subsets in immunoregulation.
###end article-title 58
###begin article-title 59
Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity.
###end article-title 59
###begin article-title 60
TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs.
###end article-title 60
###begin article-title 61
Regulation of immune responses by TGF-beta.
###end article-title 61
###begin article-title 62
###xml 36 39 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cytokines and cytokine therapies in HIV infection.
###end article-title 62
###begin article-title 63
###xml 146 151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection.
###end article-title 63
###begin article-title 64
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells.
###end article-title 64
###begin article-title 65
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
###end article-title 65
###begin article-title 66
Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells.
###end article-title 66
###begin article-title 67
Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.
###end article-title 67
###begin article-title 68
CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naive CD4+ T cells.
###end article-title 68
###begin article-title 69
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential expression of cytokine genes in HIV-1 tat transfected T and B cell lines.
###end article-title 69
###begin article-title 70
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat: immunosuppression via TGF-beta1 induction.
###end article-title 70
###begin article-title 71
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection.
###end article-title 71
###begin article-title 72
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.
###end article-title 72
###begin article-title 73
The B7 family revisited.
###end article-title 73
###begin article-title 74
Mechanisms of suppression by suppressor T cells.
###end article-title 74
###begin article-title 75
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction.
###end article-title 75
###begin article-title 76
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention.
###end article-title 76
###begin article-title 77
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
###end article-title 77
###begin article-title 78
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule.
###end article-title 78
###begin article-title 79
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.
###end article-title 79
###begin article-title 80
Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.
###end article-title 80
###begin article-title 81
###xml 9 16 <span type="species:ncbi:1392">anthrax</span>
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways.
###end article-title 81
###begin article-title 82
###xml 23 26 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Presence of Suppressor HIV-Specific CD8+ T Cells Is Associated with Increased PD-1 Expression on Effector CD8+ T Cells.
###end article-title 82
###begin article-title 83
Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.
###end article-title 83
###begin article-title 84
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 109 112 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis.
###end article-title 84
###begin article-title 85
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
###end article-title 85
###begin article-title 86
###xml 22 25 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 62 74 <span type="species:ncbi:9606">participants</span>
Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response?
###end article-title 86
###begin article-title 87
Regulatory T cells in virus infections.
###end article-title 87
###begin article-title 88
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 102 105 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.
###end article-title 88
###begin article-title 89
Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells.
###end article-title 89
###begin article-title 90
###xml 41 44 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 58 79 <span type="species:ncbi:9534">African green monkeys</span>
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS.
###end article-title 90
###begin article-title 91
About CD4pos CD25pos regulatory cells.
###end article-title 91
###begin article-title 92
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
###end article-title 92
###begin article-title 93
An essential role for Scurfin in CD4+CD25+ T regulatory cells.
###end article-title 93
###begin article-title 94
###xml 77 82 <span type="species:ncbi:9606">human</span>
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.
###end article-title 94
###begin article-title 95
###xml 74 79 <span type="species:ncbi:9606">human</span>
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.
###end article-title 95
###begin article-title 96
The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.
###end article-title 96
###begin article-title 97
Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells.
###end article-title 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 98
###begin p 99
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 119 122 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding: Work was supported by NIH grants AI43885, MH54907, AI71772, and California Research Center for the Biology of HIV in Minorities grant, UC Davis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 99

